LncRNA HLA Complex Group 11 Knockdown Alleviates Cisplatin Resistance in Gastric Cancer by Targeting the miR-144-3p/UBE2D1 Axis

OBJECTIVE: Cisplatin (DDP) treatment is one of the most predominant chemotherapeutic strategies for patients with gastric cancer (GC). LncRNA noncoding RNA HLA complex group 11 (lncRNA HCG11) has been confirmed to promote GC progression. This study attempted to investigate the underlying molecular m...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yu, Wang, Liqin, Xu, Xiaoyi, Sun, Heng, Wu, Leilei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493275/
https://www.ncbi.nlm.nih.gov/pubmed/34629901
http://dx.doi.org/10.2147/CMAR.S329846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493275/
https://www.ncbi.nlm.nih.gov/pubmed/34629901
http://dx.doi.org/10.2147/CMAR.S329846

Ejemplares similares